Pricing Log in Create free account
Wednesday 11 November 2026 Export VIR’s income statement to Excel — free account

Vir Biotechnology, Inc.

VIR

Healthcare Biotechnology

Vir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.

Revenue
−178.3%
EPS
+51.4%
Free cash flow
+36.8%

Quarter to September 2026, against a year earlier

13.12 0.03 −0.23%
Market cap
$2.3B
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
4/9
ROIC
−30.3%
Net debt / EBITDA
1.0×
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Vir Biotechnology, Inc. (VIR) P/B ratio

Alert me on P/B ratio

As of 11 November 2026, Vir Biotechnology, Inc. (VIR) trades at a P/B ratio of 2.5×. Over the past ten years it has ranged from 0.0× (December 2019) to 13.8× (January 2021); the current reading is higher than 72% of that period. That is above the Biotechnology industry median of 2.3× and in line with the Healthcare sector median of 2.4×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 1.1× 25.56%
FY2024 0.9× (1.94%)
FY2023 0.9× (44.26%)
FY2022 1.6× (58.13%)
FY2021 3.8× (14.68%)
FY2020 4.5× 394.28%
FY2019 0.9× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period P/B ratio Change
Sep 2026 2.1× 21.42%
Jun 2026 1.7× 7.08%
Mar 2026 1.6× 48.83%
Dec 2025 1.1× 9.53%
28 more quarters

Against its own ten years

Low 0.0× High 13.8×
Ten-year median 1.6×
Current reading's percentile 71

P/B ratio against peers

Company P/B ratio
BHVN Biohaven Ltd. compare n/m
LKFT Lakefront Biotherapeutics - Sponsored ADR compare 0.6×
RXRX Recursion Pharmaceuticals, Inc. compare 2.1×
VIR Vir Biotechnology, Inc. 2.5×
NAMS NewAmsterdam Pharma Company N.V. compare 4.1×
IMNM Immunome, Inc. compare 4.8×
ZYME Zymeworks Inc. compare 8.1×
REPL Replimune Group, Inc. compare 11.2×
TRAX First Tracks Biotherapeutics, Inc. compare 11.9×
Biotechnology industry median 2.3×
Healthcare sector median 2.4×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on VIR